Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.34

0.0%

Nov 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: trevor john wilkinson who started this subject	12/11/2001 5:43:31 AM
From: nigel bates	Read Replies (1) of 1475

Possible Treatment for Graft-versus-Host Disease An experimental treatment currently under development by Celmed BioSciences, a Montreal-based cell therapy company and subsidiary of Theratechnologies, has been shown to prevent Graft-versus-Host Disease (GvHD), an extremely severe and frequent condition associated with allogenic bone marrow transplants (from non-compatible donor), while preserving the immune response and the anti-cancer effect that are sought in bone marrow transplants... bio.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next